|

Ficerafusp alfa Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: BCA101, FmAb2

Pipeline

Phase 2: 1Phase 2/3: 1

Top Sponsors

  • Dana-Farber Cancer Institute1
  • Bicara Therapeutics1

Indications

  • Cancer2
  • Squamous Cell Carcinoma of the Head and Neck1
  • Recurrent Head and Neck Squamous Cell Carcinoma1
  • Metastatic Head and Neck Squamous Cell Carcinoma1
  • Head and Neck Squamous Cell Carcinoma (HNSCC)1

Birmingham, Alabama1 trial

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

Site # 0137

Phase 2/3

Boston, Massachusetts1 trial

Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC

Brigham and Women's Hospital

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.